Phospholipid oxidation and carotenoid supplementation in Alzheimer’s disease patients
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Authors
Ademowo, O.S.Dias, H.K.I.
Milic, I.
Devitt, A.
Moran, R.
Mulcahy, R.
Howard, A.N.
Nolan, J.M.
Griffiths, H.R.
Affiliation
Aston University BirminghamWaterford Institute of Technology, Ireland
Waterford University Hospital, Ireland
University of Cambridge
University of Surrey
Issue Date
2017-03-14
Metadata
Show full item recordAbstract
Alzheimer's disease (AD) is a progressive, neurodegenerative disease, characterised by decline of memory, cognitive function and changes in behaviour. Generic markers of lipid peroxidation are increased in AD and reactive oxygen species have been suggested to be involved in the aetiology of cognitive decline. Carotenoids are depleted in AD serum, therefore we have compared serum lipid oxidation between AD and age-matched control subjects before and after carotenoid supplementation. The novel oxidised phospholipid biomarker 1-palmitoyl-2-(5′-oxo-valeroyl)-sn-glycero-3-phosphocholine (POVPC) was analysed using electrospray ionisation tandem mass spectrometry (MS) with multiple reaction monitoring (MRM), 8-isoprostane (IsoP) was measured by ELISA and ferric reducing antioxidant potential (FRAP) was measured by a colorimetric assay. AD patients (n=21) and healthy age-matched control subjects (n=16) were supplemented with either Macushield™ (10 mg meso-zeaxanthin, 10 mg lutein, 2 mg zeaxanthin) or placebo (sunflower oil) for six months. The MRM-MS method determined serum POVPC sensitively (from 10 µl serum) and reproducibly (CV=7.9%). At baseline, AD subjects had higher serum POVPC compared to age-matched controls, (p=0.017) and cognitive function was correlated inversely with POVPC (r=−0.37; p=0.04). After six months of carotenoid intervention, serum POVPC was not different in AD patients compared to healthy controls. However, POVPC was significantly higher in control subjects after six months of carotenoid intervention compared to their baseline (p=0.03). Serum IsoP concentration was unrelated to disease or supplementation. Serum FRAP was significantly lower in AD than healthy controls but was unchanged by carotenoid intervention (p=0.003). In conclusion, serum POVPC is higher in AD patients compared to control subjects, is not reduced by carotenoid supplementation and correlates with cognitive function.Citation
Ademowo, O.S., Dias, H.K.I., Milic, I., Devitt, A., Moran, R., Mulcahy, R., Howard, A.N., Nolan, J.M. and Griffiths, H.R., (2017). 'Phospholipid oxidation and carotenoid supplementation in Alzheimer’s disease patients'. Free Radical Biology and Medicine, 108, pp.77-85. DOI: 10.1016/j.freeradbiomed.2017.03.008Publisher
Elsevier BVJournal
Free Radical Biology and MedicineDOI
10.1016/j.freeradbiomed.2017.03.008Additional Links
http://dx.doi.org/10.1016/j.freeradbiomed.2017.03.008https://pure.aston.ac.uk/ws/portalfiles/portal/21811873
Type
ArticleLanguage
enISSN
0891-5849ae974a485f413a2113503eed53cd6c53
10.1016/j.freeradbiomed.2017.03.008
Scopus Count
Collections
The following license files are associated with this item:
- Creative Commons